Address
15, Amazon Street, Maitama District, FCT, Nigeria.
Work Hours
Monday to Friday: 9AM - 5PM
The fight against malaria in Nigeria is set to enter a transformative chapter with the introduction of the malaria vaccine into our routine immunization schedule. The Executive Director of the National Primary Health Care Development Agency (NPHCDA), Dr. Muyi Aina, announced the rollout of the R21 malaria vaccine during an interview with the News Agency of Nigeria (NAN) on Friday, 29th November 2024, in Abuja. Beginning today, 2nd December 2024, this phased rollout will commence in Bayelsa and Kebbi states as pilot states. The vaccine will be administered to children aged 5–11 months.
Malaria continues to be one of Nigeria’s most pressing health challenges. Nigeria accounts for at least 27% of global malaria cases and 31% of malaria deaths (WHO). This burden disproportionately affects children under five, who are most vulnerable to severe illness and death. With this vaccine, Nigeria is projected to significantly reduce malaria incidence and mortality, aligning with global malaria control targets. The R21 malaria vaccine, which will be administered in four doses, is expected to serve as a critical tool to enhance existing prevention strategies, including the use of insecticides, insecticide-treated nets and antimalarial drugs.
The vaccine introduction will be implemented in three phases. Phase 1 includes a pilot in Bayela and Kebbi states. Both states were chosen based on specific criteria including high prevalence of malaria, geographic representation and vaccine supply. Phase 2 will feature an expansion to the next 19 states + FCT with high burdens of malaria. Phase 3 will involve the remaining 15 states.
Dr Aina mentioned that the vaccination exercise would target an estimated 1.5 million children in the two Phase 1 states, with health workers visiting homes and health centres to administer the vaccine. He urged residents of Bayelsa and Kebbi to actively participate in the vaccination drive, emphasizing its safety, efficacy, and importance in achieving Nigeria’s malaria elimination goals.
As Nigeria embarks on this journey, stakeholders including policymakers, healthcare providers, and civil society organizations are encouraged to collaborate to ensure success. WAVA remains committed to supporting awareness campaigns, fostering community trust in vaccines, and advocating for equity and accessibility in public health interventions.
Join in championing this historic step forward. Together, we can protect Nigeria’s children and move closer to a malaria-free future.